Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (371)	2/3/1999 10:16:00 PM
From: RCMac	Respond to of 613

TD, Here's the link to the genetic screening Newsweek article: newsweek.com --RCM

To: Arthur Radley who wrote (371)	2/4/1999 3:34:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 613

doctors can now test for genes that cause these adverse reactions to certain drugs my two cents...the first thing that popped into my head was too expensive>>let's back up to something more economical>>antisense>>buy Sepracor (for what it's worth) By the way...my thoughts after going through some more of the bioinformatics stuff--I'd like to pick a database expert's brains about any potential advantages that each of these companies might have, I am thinking the data-mining part of the puzzle is the most significant part of the problem, followed by all issues of speed associated with the hardware part of the bioinformatics problem.